Concepedia
Statistics
Publications
12
Citations
2.3K
H-Index
11
Active since
1998
Affiliations
Samsung Medical Center(Current)
Sungkyunkwan University
National Cancer Center
University of Ulsan
Seoul National University
Ho-Yeong Lim is an author at Samsung Medical Center specializing in oncology, medicine, and cancer pharmacology.
Publications per year
1998–2020
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim et al. · JAMA Oncology · 2020 · 1.2K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study
Jordi Bruix, Won Young Tak, Antonio Gasbarrini et al. · European Journal of Cancer · 2013 · 256 citations · Full text
Medicine, Oncology, Pharmacology +15
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 250 citations · Full text
Medicine, Oncology, Pharmacology +17
Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC
Riccardo Lencioni, Robert Montal, Ferràn Torres et al. · Journal of Hepatology · 2017 · 227 citations · Full text
Medicine, Oncology, Survival Analysis +12
Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial
RobinKate Kelley, Baek‐Yeol Ryoo, Philippe Merle et al. · ESMO Open · 2020 · 84 citations · Full text
Medicine, Oncology, Pharmacotherapy +14
1–5 of 12